Dr. Patrick Dion is an Assistant Professor in the Department of Neurology and Neurosurgery at the Montreal Neurological Institute affiliated to McGill University. He obtained his M.Sc. and Ph.D. at Université de Sherbrooke (Sherbrooke, Canada) and Université de Montréal (Montreal, Canada), respectively, where he studied mechanisms of oncoviral cell transformation and the mutagenic specificity of alkylating agents at specific regions of the genome. His postdoctoral research was carried out at the Hospital for Sick Children of Toronto (Toronto, Canada) and later in the Centre for Neuroscience Research of McGill University (Montreal, Canada).
Prior to his move to the Neurological Institute in 2013, he was an Assistant Professor in the Department of Pathology and Cell Biology of Université de Montréal. Dr Dion is interested in the identification of novel genetic risk factors in a range of neurological conditions (amyotrophic lateral sclerosis, essential tremor, restless legs syndrome) as well as into the characterization of the underlying pathogenic events associated with these risk factors. He contributed to a number of studies in the field of ALS, and in 2015 his study of the nuclear pore component, Gle1, opened the door to a range of reports observing nuclear-cytoplasmic export defects where Gle1 and other component of the nuclear pore were observed to be mislocalized.
Dr. Guy Rouleau is the Director of the Montreal Neurological Institute and Hospital (The Neuro) affiliated to McGill University (Montreal, Canada). Over the last 25 years, Dr. Guy Rouleau and his team have focused on identifying the genes causing several neurological and psychiatric diseases, including autism, amyotrophic lateral sclerosis, hereditary neuropathies, epilepsy and schizophrenia, as well as providing a better understanding of the molecular mechanisms that lead to these disease symptoms. In 2017 he launched the Tanenbaum Open Science Institute (TOSI) aimed to accelerated the generation of knowledge and novel effective treatments for brain disorders by freeing science.
Dr. Rouleau’s main achievements are his contribution to the identification of dozens of disease causing genes and his discovery of new mutational mechanisms. In regard to ALS he has overseen the implementation of an iPSC facilities where assays and models are being studied to develop assays using cells from patients differentiated into disease relevant cell types. Dr. Rouleau has published nearly 800 articles in peer‐reviewed journals and has been quoted more than 65,000 times (Google Scholar). He has supervised more than a hundred students at the Masters, PhD and post‐doctoral levels in addition to receiving numerous awards for his contribution to science and society.
Dr. Daniel Zytnicki is a neurophysiologist. He performed his PhD work in the laboratory of Professor Y. Laporte at the Collège de France under the supervision of Léna Jami before moving for a post-doc to the University of Göteborg in the Lundberg's laboratory under the supervision of Elzbieta Jankowska. He was recruited in 1984 as a junior researcher at CNRS and since 1998, is a CNRS Research Director. He is currently working at the Paris Descartes University where he is leading the "Spinal Physiology and Pathophysiology team". In this University, he founded an interdisciplinary research unit, the Laboratory of Neurophysics and Physiology and he has directed the Research Federation in Neuroscience from 2014 to 2018.
His long-standing research work aims at elucidating 1°) how the proprioceptive inputs control the activity of motoneurons, i.e. the output stage of all motor systems, and 2°) the pathophysiological mechanisms that lead to degeneration of motoneurons in amyotrophic lateral sclerosis (ALS). He is an expert in electrophysiological studies in vivo. In particular, he applied the dynamic clamp technique to the in vivo investigation of spinal motoneurons, and he used this breakthrough to unravel how intrinsic conductances of motoneurons interplay to produce a physiologically consistent electrical activity. Together with Dr. Marin Manuel, he has developed an in vivo mouse preparation that allowed them to obtain very stable intracellular recordings in spinal motoneurons. Thanks to this preparation, they have investigated the intrinsic properties of spinal motoneurons from adult mice in normal state. Later on, they applied their expertise to investigate the properties of motoneurons and the spinal circuitry in ALS.Dr. Zytnicki has received in 2000 the Foulon prize from the French Academy of Sciences for his work on the proprioceptive control of motoneurons.
Dr. Francesco Roselli is Principal Investigator in the Department of Neurology at the University of Ulm. After receiving his medical degree and board qualification in neurology at Bari University School of Medicine, he was trained on the synaptic mechanisms of Alzheimer Disease in the laboratory of Prof. Osborne Almeida at the Max-Planck Institute of Psychiatry (obtaining his PhD in Experimental Neurobiology); he then joined the laboratory led of Prof. Pico Caroni at the Friedrich Miescher Institute in Basel, where he worked on chemogenetic manipulation of neurodegenerative pathways and on activity-dependent mechanisms of neuroprotection in amyotrophic lateral sclerosis.
As an independent investigator, he is pursuing the role of circuit and mesoscale factors in determining the vulnerability of neurons to different acute and chronic insults and he is exploring the manipulation of synaptic inputs to deliver neuroprotection. Dr. Roselli exploits a set of viral vectors, chemogenetic approaches, advanced imaging and multiple murine and iPSC models to investigate ALS, traumatic brain injury and collaborates extensively with partners in clinical neurology and in industry to bring the basic-science advancement to the bedside of patients.
He has received an EMBO long-term fellowship and research support from the Synapsis Foundation, the Thierry-Latran Foundation, the Baustein program of Ulm University-Medical faculty, the Deutsche Forschungsgemenischaft, the ERANET-NEURON program and from Hoffmann-La Roche and Bayer.
Prof. A.C. Kato
President of the Scientific Advisory Board
Faculty of Medicine , University of Geneva, 1211 Geneva 4, Switzerland
Please no faxes or telephone calls. You will receive a response in December 2019.
© 2018 Radala Foundation . All rights reserved | Design by W3layouts